Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Start-up to develop radiotherapeutics

by Michael McCoy
March 6, 2017 | A version of this story appeared in Volume 95, Issue 10

Fusion Pharmaceuticals has launched to develop α-particle radiotherapeutics for treating cancer. The new firm, based in Hamilton, Ontario, received $25 million in series A financing from Johnson & Johnson and other investors. Fusion was founded by John Valliant, a chemist who also founded the Centre for Probe Development & Commercialization at Canada’s McMaster University. Fusion’s lead product, FPX-01, will deliver actinium-225 to tumor cells with the help of a centyrin-based targeting molecule from J&J’s Janssen Biotech unit.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.